GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches
Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed.
Granulocyte–macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor …
Granulocyte–macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor …
Advances in the treatment of giant cell arteritis
S Castañeda, D Prieto-Peña… - Journal of clinical …, 2022 - mdpi.com
Giant cell arteritis (GCA) is the most common vasculitis among elderly people. The clinical
spectrum of the disease is heterogeneous, with a classic/cranial phenotype, and another …
spectrum of the disease is heterogeneous, with a classic/cranial phenotype, and another …
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
MC Cid, SH Unizony, D Blockmans… - Annals of the …, 2022 - ard.bmj.com
Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in
pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor …
pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor …
Distinct macrophage phenotypes skewed by local granulocyte macrophage colony‐stimulating factor (GM‐CSF) and macrophage colony‐stimulating factor (M‐CSF) …
WF Jiemy, Y van Sleen… - Clinical & …, 2020 - Wiley Online Library
Objective To determine the presence and spatial distribution of different macrophage
phenotypes, governed by granulocyte macrophage colony‐stimulating factor (GM‐CSF) and …
phenotypes, governed by granulocyte macrophage colony‐stimulating factor (GM‐CSF) and …
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients …
M Corbera-Bellalta, R Alba-Rovira… - Annals of the …, 2022 - ard.bmj.com
Background Effective and safe therapies are needed for the treatment of patients with giant
cell arteritis (GCA). Emerging as a key cytokine in inflammation, granulocyte-macrophage …
cell arteritis (GCA). Emerging as a key cytokine in inflammation, granulocyte-macrophage …
Diagnosis and management of giant cell arteritis: Major review
S Simon, J Ninan, P Hissaria - Clinical & Experimental …, 2021 - Wiley Online Library
Giant cell arteritis is a medical emergency because of the high risk of irreversible blindness
and cerebrovascular accidents. While elevated inflammatory markers, temporal artery …
and cerebrovascular accidents. While elevated inflammatory markers, temporal artery …
Need and value of targeted immunosuppressive therapy in giant cell arteritis
Despite the heterogeneity of the giant cell arteritis (GCA) at the level of clinical
manifestations and the cellular and molecular players involved in its pathogenesis, GCA is …
manifestations and the cellular and molecular players involved in its pathogenesis, GCA is …
Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies
MC Cid, R Rios-Garces, N Terrades-Garcia… - …, 2020 - academic.oup.com
For decades, the treatment of GCA has relied on glucocorticoids. Work over the past two
decades has supported a modest efficacy of MTX but no clear benefit from anti-TNF-based …
decades has supported a modest efficacy of MTX but no clear benefit from anti-TNF-based …
Reducing the toxicity of long-term glucocorticoid treatment in large vessel vasculitis
A Palmowski, F Buttgereit - Current Rheumatology Reports, 2020 - Springer
Abstract Purpose While glucocorticoids (GCs) are effective in large vessel vasculitis (LVV),
they may cause serious adverse events (AEs), especially if taken for longer durations and at …
they may cause serious adverse events (AEs), especially if taken for longer durations and at …
Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?
P Harkins, R Conway - Expert Opinion on Investigational Drugs, 2022 - Taylor & Francis
ABSTRACT Introduction Giant Cell Arteritis (GCA) is the most common systemic vasculitis
worldwide. For decades, glucocorticoids have represented the mainstay of treatment, at the …
worldwide. For decades, glucocorticoids have represented the mainstay of treatment, at the …